A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
PHASE4
This 2 arm study will assess the efficacy, safety and tolerability of subcu...
Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis
PHASE2
This sequential study will assess the efficacy and safety of multiple doses...
Status
Completed
Location
Royal Children'S Hospital; Department of Nephrology
OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis
N/A
This prospective observational study evaluated the efficacy and safety of M...